UM
Uday Madhusudan Raval
About Uday Madhusudan Raval
Data last updated:
Uday Madhusudan Raval has 34 years in corporate governance. Holds Director role. Currently with 1 company, including Relic Pharma Limited. Formerly with 4 companies, such as Relic Technologies Limited and Arkaan Enterprises Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 04 May 1995 | 1995 | – | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 06 Dec 1991 | 1991 | ₹2.05 Cr (FY 2025) | Active | |
| Director | 08 Nov 1993 | 1993 | ₹3.4 Lakh (FY 2025) | Active | |
| Director | 05 Sep 1994 | 1994 | ₹11.06 Cr (FY 2025) | Active | |
| Director | 22 Dec 2007 | 1947 | ₹8.57 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Uday Madhusudan Raval
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Uday Madhusudan Raval
Uday Madhusudan Raval has 34 years in corporate governance. Holds Director role. Currently with 1 company, including Relic Pharma Limited. Formerly with 4 companies, such as Relic Technologies Limited and Arkaan Enterprises Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Uday Madhusudan Raval is associated with 1 company as Director, including Relic Pharma Limited.
Uday Madhusudan Raval has expertise in General Business, Technology.
Uday Madhusudan Raval has 34 years in corporate governance.
Uday Madhusudan Raval currently holds positions at 1 company: Relic Pharma Limited.